Product Description: Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis. Gavilimomab can be used for the research of graft-versus-host disease (GVHD)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Deeg HJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 1;98(7):2052-8.